e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello
Source:
Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Journal Issue:
October
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello. Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders. Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020
Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Year: 2019
Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence
Source: Eur Respir J 2010; 36: 709-711
Year: 2010
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity
Source: Eur Respir J 2006; 27: 230-232
Year: 2006
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1426-1433
Year: 2015
Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009
Experience of using Janus kinase inhibitors in COVID-19
Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment
Year: 2021
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Role of IκB kinases (IKKs) α and β in severe asthma and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 2s
Year: 2005
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study
Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018
Year: 2019
Increased activation of p38 MAPK in COPD
Source: Eur Respir J 2008; 31: 62-69
Year: 2008
Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
Source: Eur Respir J 2013; 41: 3-4
Year: 2013
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Source: Eur Respir Rev 2017; 26: 160004
Year: 2017
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Pulmonary hypertension in patients with chronic myeloproliferative disorders
Source: Eur Respir Rev 2015; 24: 400-410
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept